ReviewBiomedicines2021
Mucus, Microbiomes and Pulmonary Disease.
Review in Biomedicines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 45 citations in OpenAlex.
- Targeting Inflammation in Bronchiectasis.Drugs · 2026Review
- Epithelial cells in chronic obstructive pulmonary disease exacerbations: Targets for lung repair.Pharmacological reviews · 2026Review
- Airway Mucosal Defense: Mucins, Innate Immunity, and Contemporary Mucoactive Strategies.Biomedicines · 2026Review
- Mucin stimulates the growth ofMicrobiology (Reading, England) · 2026Article
- Clinical features and risk factors of plastic bronchitis in Mycoplasma pneumoniae pneumonia children with pulmonary consolidation: a prospective cohort study.Frontiers in pediatrics · 2026Article
- Respiratory bacteriome and its predicted functional profiles in blue whales (Balaenoptera musculus).Scientific reports · 2025Article
- Integrated multi-omics profiling for risk stratification in Asians with COPD.Respiratory research · 2025Article
- Voriconazole-Loaded Nanohydrogels Towards Optimized Antifungal Therapy for Cystic Fibrosis Patients.Pharmaceutics · 2025Article
- Airway Mucus Plugs on Chest Computed Tomography Are Associated with Exacerbations in Chronic Obstructive Pulmonary Disease.American journal of respiratory and critical care medicine · 2025Article
- Biofilm Resilience: Molecular Mechanisms Driving Antibiotic Resistance in Clinical Contexts.Biology · 2025Review
- Modulation of pulmonary immune functions by theFrontiers in immunology · 2025Review
- The forecasting power of the mucin-microbiome interplay in livestock respiratory diseases.The veterinary quarterly · 2024Article
- Optimization of lung tissue pre-treatment by bead homogenization for subsequent culturomics.Scientific reports · 2024Article
- Article
- Iron content of commercial mucin contributes to compositional stability of a cystic fibrosis airway synthetic microbiota community.bioRxiv : the preprint server for biology · 2024Article
- Accelerated Lung Function Decline and Mucus-Microbe Evolution in Chronic Obstructive Pulmonary Disease.American journal of respiratory and critical care medicine · 2024Observational
- Unsung Heroes? Decoding the Protective Effects of Airway Microbiota in Chronic Obstructive Pulmonary Disease.American journal of respiratory and critical care medicine · 2024Article
- SERS sensing for cancer biomarker: Approaches and directions.Bioactive materials · 2024Review
- Hydroxypropyl-Beta Cyclodextrin Barrier Prevents Respiratory Viral Infections: A Preclinical Study.International journal of molecular sciences · 2024Article
- Impact of particulate air pollution on airway injury and epithelial plasticity; underlying mechanisms.Frontiers in immunology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The respiratory tract harbors a stable and diverse microbial population within an extracellular mucus layer. Mucus provides a formidable defense against infection and maintaining healthy mucus is essential to normal pulmonary physiology, promoting immune tolerance and facilitating a healthy, commensal lung microbiome that can be altered in association with chronic respiratory disease. How one maintains a specialized (healthy) microbiome that resists significant fluctuation remains unknown, although smoking, diet, antimicrobial therapy, and infection have all been observed to influence microbial lung homeostasis. In this review, we outline the specific role of polymerizing mucin, a key functional component of the mucus layer that changes during pulmonary disease. We discuss strategies by which mucin feed and spatial orientation directly influence microbial behavior and highlight how a compromised mucus layer gives rise to inflammation and microbial dysbiosis. This emerging field of respiratory research provides fresh opportunities to examine mucus, and its function as predictors of infection risk or disease progression and severity across a range of chronic pulmonary disease states and consider new perspectives in the development of mucolytic treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.